NIGP 26910: Antineoplastic Agents

NIGP 26910 Antineoplastic Agents, an Item code, covers chemotherapy drugs and related pharmaceutical agents used in cancer treatment that state and local health systems, correctional facilities, and public hospitals procure through both direct purchase and group purchasing organizations. The scope includes branded and generic formulations across multiple drug classes — alkylating agents, antimetabolites, topoisomerase inhibitors, targeted therapies, and immunotherapies — typically sourced through pharmaceutical wholesalers, manufacturers' patient assistance programs, or cooperative purchasing agreements negotiated by state Medicaid agencies, public hospital systems, or specialized oncology networks. Issuing bodies include state departments of health, state prison systems, county health departments, city and county hospitals, and independent public hospital districts. Procurement often occurs through RFQs to multiple manufacturers or wholesalers, with volume commitments and pricing negotiations driven by patient census, treatment protocols, and budget cycles aligned to fiscal years.

The source provided contains no recent state and local contract opportunities or geographic activity data for this code. Without posted RFPs, RFQs, IFBs, or ITBs in the available record, current market activity, issuing-body concentration, and geographic concentration cannot be characterized from recent solicitation evidence.